Next Investors logo grey

MXC on clear path to enter multi-million-dollar Australian medical cannabis market


Published 20-NOV-2017 12:56 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Europe-based medicinal cannabis company, MGC Pharmaceuticals (ASX:MXC), today revealed that it has executed a binding definitive exclusive supply agreement with specialist pharmaceutical wholesaler and distributor, HL Pharma, to bring its adult epilepsy product, CannEpilTM, to the Australian market from early 2018.

This follows on from the signing of a heads of agreement (HoA) with HL Pharma, as announced at the beginning of the month.

This deal is set to generate considerable annual revenues for MXC, with the product delivering strong gross profit margins. MXC’s Pharma division plans to manufacture the product at its world-class Slovenian facility, which is currently undergoing GMP certification.

MXC now has a clear pathway for delivering the first MGC Pharmaceuticals medicinal cannabis products to the multi-million-dollar Australian market. The product will launch early next year, once HL Pharma has obtained all necessary approvals for importing the product.

MXC already has strong ties to Epilepsy Action Australia (EAA), with whom it is working closely to rapidly build an Australian patient market through an expanding network of authorised prescribing Australian doctors.

An initial group of at least five doctors have already formally registered interest in prescribing the product, and are currently in the process of applying for authorised prescriber status with Australian regulatory authorities.

MGC Pharmaceuticals is expected to generate around $1 million next year alone from a small starting pool of 100 registered patients. This has strong potential to increase, given the expansive Australian market.

The CannEpil product targets drug-resistant epilepsy (also known as refractory epilepsy), which accounts for around 30% of the 25,000 cases that are diagnosed in Australia each year.

More broadly, according to the EAA, around 25,000 people are diagnosed with epilepsy each year, and up to 240,000 Australians are currently living with epilepsy.

How much of this market MXC will be able to reach is yet to be determined so investors should seek professional financial advice if considering this stock for their portfolio.

The product will be made available to patients with an authorised doctor’s prescription for a regular retail price under A$800 – significantly lower than competing products currently on the market, making this an appealingly affordable option for patients.

mgc pharmaceuticals

HL Pharma has over 20 years of experience as a specialist supplier of unregistered pharmaceutical products (these are not registered with the Therapeutic Goods Agency (TGA), but are registered with other recognised pharmaceutical regulators) in Australia. It only sources products from registered suppliers with a pharmaceutical wholesale or manufacturing license and are registered with the Medicines and Health Regulatory Agency (MHRA) in the UK.

According to the terms of the agreement, HL Pharma is required to first work with MXC for provision of relevant products for distribution in the future within Australia before seeking out other potential suppliers.

Roby Zomer, MXC co-founder and CEO, said: “We now have a clear view on the pathway to the commencement of an Australian sales pipeline and revenue stream for our medical cannabis products which is a key milestone for our company and is further evidence of the strong momentum that we are building through the execution of revenue generating agreements.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.